Guide
Unlocking insights with AlphaLISA anti-drug antibodies detection assays
Biological drug products often trigger immune responses in patients, and the presence of Anti-Drug Antibodies (ADAs) can have varying clinical consequences—from mild to serious adverse events. To ensure safety and efficacy, evaluating and correlating ADAs with pharmacological or toxicological observations is crucial. Enter AlphaLISA technology—a bead-based luminescent proximity assay. By detecting anti-drug antibodies, it provides rapid and sensitive results, making it an essential step in drug development.
In this guide, we explore the science behind AlphaLISA™ ADA detection assays, bridging assay configurations, and practical protocols. This resource equips you with the knowledge needed to navigate ADA assessment effectively.
For research use only. Not for use in diagnostic procedures.
Download Resource
Unlocking insights with AlphaLISA anti-drug antibodies detection assays